ClinicalTrials.gg
CompletedNCT00680446Updated Jun 19, 2013

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

A Phase 3 interventional study of Immunoglobulin G (Ig NextGen 16%) in Primary Immune Deficiency, sponsored by CSL Limited. Completed at 9 sites in 2 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2013-06-19.

Sponsored by CSL Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.

Enrollment
17th of 28
41 · median 45
Started
2008
the only one that year
Phase 3
20 of 29
2 open now
Registered
7th of 29
by date
Lead sponsor
1 of 29
CSL Limited

Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2008, is one of 20 in phase 3, and was the 7th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulin G

Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.

Read the detailed description

This is a Phase 3, open label, multi-centre, study for patients requiring Ig replacement therapy. This study is a follow-on study to patients who have completed the CSLCT-SCIG-05-23 clinical trial and wish to continue subcutaneous treatment with Ig NextGen 16% . Additionally, patients currently receiving IVIg with unacceptable adverse reactions or unable to tolerate IVIg as well as patients receiving alternate IG products via the SC route may be enrolled in this study. Patients must not be eligible for any of the Sponsor's ongoing PID studies that are still open to enrolment.

03

Conditions studied

  • Primary Immune Deficiency

Keywords

  • Primary Immune Deficiency
  • Subcutaneous
  • Immunoglobulin G
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >3 years of age.
  2. PID patients receiving Ig replacement therapy.
  3. Patients must have completed or withdrawn from CSLCT-SCIG-05-23 and wish to continue SCIg therapy; or, patients ineligible for CSLCT-SCIG-05-23 but for whom the Investigator believes SCIg may be a suitable form of Ig replacement, for reasons such as: poor tolerability of IVIg, difficult venous access, or, preferred route of administration.
  4. Patient is capable of self-administering Ig NextGen 16%

Exclusion criteria

Exclusion Criteria:

  1. Patients eligible for CSLCT-SCIG-05-23 if still open for recruitment.
  2. Patients with known anaphylaxis reactions to immunoglobulin therapy.
  3. Patients with known selective IgA deficiency or antibodies to IgA with a history of reactions to Ig therapy.
  4. Patients with protein-losing enteropathies.
  5. Patients who are suffering from an acute or chronic medical condition, other than PID, which may, in the opinion of the Investigator, affect their treatment or the conduct of the trial.
  6. Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Females who are of child bearing potential must have a negative pregnancy test at screening.
  7. Patients unwilling to comply with the protocol.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    1

    Drug: Immunoglobulin G (Ig NextGen 16%)

Interventions

06

What researchers measure

Primary outcomes

  1. Rate, Severity and Relatedness of reported Adverse Events

    Time frame: Up to Four Years

Secondary outcomes

  1. To monitor patient IgG trough levels while receiving Ig NextGen 16%

    Time frame: Up to 4 years

07

Study locations

9 sites
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • Sydney Children's Hospital
    Randwick, New South Wales 2031, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Women's & Children's Hospital
    North Adelaide, South Australia 5006, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • Auckland Hospital
    Auckland, New Zealand
  • Christchurch Hospital
    Christchurch, New Zealand
  • Wellington Hospital
    Wellington, New Zealand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2008
First posted
May 20, 2008
Start
Apr 2008
Primary completionActual
May 2013
CompletionActual
May 2013
Last update
Jun 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00680446
Lead sponsor
CSL Limited
Responsible party
Sponsor
First posted
May 20, 2008
Start date
Apr 2008
Primary completion
May 2013
Completion
May 2013
Last update
Jun 19, 2013

Study contacts

Medical and Research Director
study director · CSL

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulin G

Start the discussion